Aspire BioPharma, Inc. (ASBP) - Total Liabilities
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has total liabilities worth $3.25 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aspire BioPharma, Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Aspire BioPharma, Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Aspire BioPharma, Inc. Competitors by Total Liabilities
The table below lists competitors of Aspire BioPharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Torr Metals Inc
V:TMET
|
Canada | CA$1.09 Million |
|
Iceni Gold Ltd
AU:ICL
|
Australia | AU$1.11 Million |
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
|
Baijiayun Group Ltd
NASDAQ:RTC
|
USA | $47.11 Million |
|
Rochester Resources Ltd
V:RCT
|
Canada | CA$51.18 Million |
|
Nexalin Technology Inc.
NASDAQ:NXL
|
USA | $808.36K |
|
Companhia Paranaense de Energia Pref ADR
NYSE:ELP
|
USA | $36.10 Billion |
|
Nordic LEVEL Group AB
ST:LEVEL
|
Sweden | Skr172.22 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Aspire BioPharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aspire BioPharma, Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aspire BioPharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual total liabilities of Aspire BioPharma, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.69 Million | +355.46% |
| 2024-12-31 | $1.69 Million | +318.54% |
| 2023-12-31 | $403.33K | -96.37% |
| 2022-12-31 | $11.12 Million | +3684.81% |
| 2021-12-31 | $293.70K | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more